D. Boral Capital reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $46.00 price target on the biotechnology company’s stock.
Separately, HC Wainwright restated a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, January 21st.
Read Our Latest Analysis on AVXL
Anavex Life Sciences Stock Up 0.9 %
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last posted its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Equities research analysts expect that Anavex Life Sciences will post -0.73 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Berkshire Money Management Inc. purchased a new position in Anavex Life Sciences during the fourth quarter worth $107,000. Stratos Wealth Partners LTD. acquired a new stake in shares of Anavex Life Sciences during the fourth quarter valued at $241,000. China Universal Asset Management Co. Ltd. increased its position in Anavex Life Sciences by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 1,671 shares in the last quarter. Foster Victor Wealth Advisors LLC raised its stake in Anavex Life Sciences by 5.6% in the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 2,000 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Anavex Life Sciences by 25.8% in the 4th quarter. SG Americas Securities LLC now owns 34,844 shares of the biotechnology company’s stock valued at $374,000 after purchasing an additional 7,138 shares in the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Recommended Stories
- Five stocks we like better than Anavex Life Sciences
- What is Put Option Volume?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- High Flyers: 3 Natural Gas Stocks for March 2022
- What Does the Future Hold for Eli Lilly?
- How to Read Stock Charts for Beginners
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.